Focal therapy using a novel cooled laser device for prostate cancer: early trial results

Key Points

• Cooled laser therapy achieves an 84% treatment success rate at 3 months post-therapy, indicating effectiveness.
• Low morbidity suggests that the procedure may be safer compared to conventional treatments for prostate cancer.
• The analysis utilized early trial results from the PFLT-PC trial to measure treatment outcomes and patient recovery.
• Findings propose that cooled laser therapy could be a promising alternative for managing prostate cancer.

Abstract